BioCentury
ARTICLE | Clinical News

Merck reports Phase I data for DNA-PK inhibitor M3814 in solid tumors

June 15, 2017 2:31 AM UTC

Merck KGaA (Xetra:MRK) reported data from 25 evaluable patients with advanced solid tumors in a Phase I trial showing that oral M3814 (MSC 2490484A) led to 6 cases of stable disease lasting for ≥18 weeks. The recommended Phase II dose is twice-daily 400 mg M3814. The most frequent adverse events reported were nausea, vomiting, reduced appetite, constipation, diarrhea, fever, fatigue and rash. Data were presented at the American Society of Clinical Oncology meeting in Chicago.

The open-label, German trial is also enrolling patients with chronic lymphocytic leukemia (CLL). The trial's primary endpoint is evaluating dose-limiting toxicities (DLTs). Secondary endpoints include pharmacokinetics, best overall response rate (ORR), clinical benefit rate (CBR) and progression-free survival (PFS)...